Back to today’s briefing

Story perspectives

Novo Nordisk Cuts Wegovy Price Amid Drug Market Competition

3/6/2025

32 4

Summary

Novo Nordisk Price Cut

Novo Nordisk is slashing the price of its popular weight-loss drug Wegovy to $499 per month for uninsured patients via NovoCare Pharmacy, a move that echoes Eli Lilly's recent price drop for Zepbound. This shift comes in response to the FDA's ruling on drug shortages, sparking fierce competition in the booming $130 billion obesity drug market.

Summary

AbbVie Tackles Obesity

AbbVie is joining forces with Danish biotech Gubra to tackle the obesity epidemic with a promising new drug, GUB014295, designed to curb appetite by mimicking amylin. This groundbreaking partnership, worth up to $1.875 billion, seeks to make a significant impact as the obesity drug market is projected to soar to $130 billion by 2030, affecting nearly 900 million adults worldwide.

History

Historical Context

Novo Nordisk's price cut for Wegovy reflects a historical trend of pharmaceutical companies responding to market pressures. Similar to the 1989 price reduction of AZT amid AIDS activism, this move illustrates how competition and public demand can drive down drug costs, influencing access to essential medications.

1 of 3

Novo Nordisk Price Cut

Novo Nordisk is slashing the price of its popular weight-loss drug Wegovy to $499 per month for uninsured patients via NovoCare Pharmacy, a move that echoes Eli Lilly's recent price drop for Zepbound. This shift comes in response to the FDA's ruling on drug shortages, sparking fierce competition in the booming $130 billion obesity drug market.

1 / 3